Clipping of news on Brazilian Culture, Law and Citizenship
03/05/2013
This article was translated by an automatic translation system, and was therefore not reviewed by people.
BOSTON - The ability to immunize babies soon after birth seems to be becoming a reality. Currently, the vaccination series begins at two months of age, because the underdeveloped immune system of newborns does not respond to most vaccines, leaving them vulnerable to high risk of infections. The good news is that researchers at Children's Hospital Boston have identified a potent compound that activates the immune responses of white blood cells of newborns, which may contribute to the development of effective vaccines at birth.
Researchers at the Division of Infectious Diseases at Children's Hospital Boston showed that while newborns are just some aspects of the immune response, your white blood cells have a receptor that responds strongly to stimulation, known as Toll-like receptor 8 (TLR8).
Toll-like receptors (TLRs), first identified in humans for nearly two decades, are part of the immune response that provides our first defense against infection. Ten types of TLRs are known, and stimulating TLR begun to be added to vaccines as an adjuvant, enhancing the result. The main monophosphoryl lipid A (MPLA), stimulates TLR4 and is used in the vaccine Cervarix, which protects against the human papillomavirus (HPV)
With encouraging results in cells from human neonates, researchers now hope to formulate a stimulator TLR8 similar to the test as a vaccine adjuvant in primates newborns, a model in which the laboratory is experienced and whose TLR8 responses to resemble those of humans.
Read more:
Source: Extra - online
Our news are removed entirely from the sites of our partners. For this reason, we can not change their content even in cases of typos.
This article was translated by an automatic translation system, and was therefore not reviewed by people.